RE:New trial update on FDA/Multiple melanomaThe myleoma story is getting long-toothed. Lots of patients treated and plenty of clinical evidence of some effect. Treating relapsed MM with Pela is aimed at extending the effectiveness of current meds and they are trying to be included in earlier treatment. Quite a good model to follow for treatment effect as you can measure residual disease with blood and urine proteins as well as cellular markers. Rather than imaging, the trials look at real-time effects. If Pela works in this indication, results are available very quickly and should be obvious. It is a bit worrisome that years have gone by with the various MM trials but this change with BMS will have to be explained by the company. I would think it is actually significantly positive
cheers, Geneman